JP7187449B2 - Ｅｈｍｔ２阻害剤としての置換された融合二環式または三環式複素環化合物 - Google Patents

Ｅｈｍｔ２阻害剤としての置換された融合二環式または三環式複素環化合物 Download PDF

Info

Publication number
JP7187449B2
JP7187449B2 JP2019517090A JP2019517090A JP7187449B2 JP 7187449 B2 JP7187449 B2 JP 7187449B2 JP 2019517090 A JP2019517090 A JP 2019517090A JP 2019517090 A JP2019517090 A JP 2019517090A JP 7187449 B2 JP7187449 B2 JP 7187449B2
Authority
JP
Japan
Prior art keywords
halo
compound
alkyl
optionally substituted
hydroxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019517090A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533650A5 (enExample
JPWO2018064557A5 (enExample
JP2019533650A (ja
Inventor
エメルソン キャンプベル ジョン
ウィリアム ダンカン ケニス
Original Assignee
エピザイム，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エピザイム，インコーポレイティド filed Critical エピザイム，インコーポレイティド
Publication of JP2019533650A publication Critical patent/JP2019533650A/ja
Publication of JP2019533650A5 publication Critical patent/JP2019533650A5/ja
Publication of JPWO2018064557A5 publication Critical patent/JPWO2018064557A5/ja
Priority to JP2022192370A priority Critical patent/JP2023022230A/ja
Application granted granted Critical
Publication of JP7187449B2 publication Critical patent/JP7187449B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
JP2019517090A 2016-09-30 2017-09-29 Ｅｈｍｔ２阻害剤としての置換された融合二環式または三環式複素環化合物 Active JP7187449B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022192370A JP2023022230A (ja) 2016-09-30 2022-11-30 Ｅｈｍｔ２阻害剤としての置換された融合二環式または三環式複素環化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662402863P 2016-09-30 2016-09-30
US62/402,863 2016-09-30
US201762509620P 2017-05-22 2017-05-22
US62/509,620 2017-05-22
PCT/US2017/054468 WO2018064557A1 (en) 2016-09-30 2017-09-29 Substituted fused bi- or tri- heterocyclic compounds as ehmt2 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022192370A Division JP2023022230A (ja) 2016-09-30 2022-11-30 Ｅｈｍｔ２阻害剤としての置換された融合二環式または三環式複素環化合物

Publications (4)

Publication Number Publication Date
JP2019533650A JP2019533650A (ja) 2019-11-21
JP2019533650A5 JP2019533650A5 (enExample) 2020-11-12
JPWO2018064557A5 JPWO2018064557A5 (enExample) 2022-10-11
JP7187449B2 true JP7187449B2 (ja) 2022-12-12

Family

ID=60043417

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019517090A Active JP7187449B2 (ja) 2016-09-30 2017-09-29 Ｅｈｍｔ２阻害剤としての置換された融合二環式または三環式複素環化合物
JP2022192370A Pending JP2023022230A (ja) 2016-09-30 2022-11-30 Ｅｈｍｔ２阻害剤としての置換された融合二環式または三環式複素環化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022192370A Pending JP2023022230A (ja) 2016-09-30 2022-11-30 Ｅｈｍｔ２阻害剤としての置換された融合二環式または三環式複素環化合物

Country Status (6)

Country Link
US (2) US20200039961A1 (enExample)
EP (2) EP4105203A1 (enExample)
JP (2) JP7187449B2 (enExample)
AU (3) AU2017336074A1 (enExample)
CA (1) CA3037587A1 (enExample)
WO (1) WO2018064557A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3060416A1 (en) 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
BR112022022409A2 (pt) 2020-05-06 2023-02-07 Ajax Therapeutics Inc 6-heteroarilóxi benzimidazóis e azabenzimidazóis como inibidores de jak2
EP4267574B1 (en) 2020-12-23 2025-04-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
WO2023086320A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of jak2
US11970494B2 (en) 2021-11-09 2024-04-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
CN116425642B (zh) * 2023-04-06 2025-06-10 浙江科聚生物医药有限公司 2-甲氧基-4-氟-5-胺基苯酚的制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002543182A (ja) 1999-05-04 2002-12-17 ワイス チオオキシインドール誘導体
JP2002543183A (ja) 1999-05-04 2002-12-17 ワイス プロゲステロンアンタゴニストとしてのインドリン誘導体
JP2007509058A (ja) 2003-10-16 2007-04-12 カイロン コーポレイション Ｒａｆキナーゼインヒビターとしての置換ベンゾアゾールおよびその使用
JP2009525313A (ja) 2006-02-03 2009-07-09 サノフイ−アベンテイス ベンゾイミダゾール単位を含む三環式ｎ−ヘテロアリール−カルボキサミド誘導体、それらの調製方法およびそれらの治療上の使用
CN103172637A (zh) 2013-03-13 2013-06-26 上海大学 嘧啶并[1,2-a]苯并咪唑类化合物及其制备方法
US20150244660A1 (en) 2005-12-06 2015-08-27 Microsoft Technology Licensing, Llc Document object model api for mime
US20150274660A1 (en) 2014-03-28 2015-10-01 Abbvie Inc. INHIBITORS OF HISTONE METHYLTRANSFERASE G9a

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8604566D0 (sv) 1986-10-27 1986-10-27 Haessle Ab Novel compunds
GB8820231D0 (en) 1988-08-25 1988-09-28 Fujisawa Pharmaceutical Co New benzazole compounds processes for preparation thereof & pharmaceutical composition comprising same
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US6025379A (en) 1996-03-11 2000-02-15 Eli Lilly And Company Methods of treating or preventing interstitial cystitis
TW593278B (en) 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
CA2952474A1 (en) 2014-06-23 2015-12-30 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
MA47233A (fr) * 2016-12-19 2019-10-23 Epizyme Inc Composés hétérocycliques substitués par une amine utilisés comme inhibiteurs de l'ehmt2 et leurs méthodes d'utilisation
EP3600318A4 (en) * 2017-03-31 2021-06-09 Epizyme, Inc. METHOD OF USING EHMT2 INHIBITORS
AU2018353139A1 (en) * 2017-10-18 2020-06-04 Epizyme, Inc. Methods of using EHMT2 inhibitors in immunotherapies
US20210260040A1 (en) * 2017-10-18 2021-08-26 Epizyme, Inc. Methods of using ehmt2 inhibitors in treating or preventing blood disorders

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002543182A (ja) 1999-05-04 2002-12-17 ワイス チオオキシインドール誘導体
JP2002543183A (ja) 1999-05-04 2002-12-17 ワイス プロゲステロンアンタゴニストとしてのインドリン誘導体
JP2007509058A (ja) 2003-10-16 2007-04-12 カイロン コーポレイション Ｒａｆキナーゼインヒビターとしての置換ベンゾアゾールおよびその使用
US20150244660A1 (en) 2005-12-06 2015-08-27 Microsoft Technology Licensing, Llc Document object model api for mime
JP2009525313A (ja) 2006-02-03 2009-07-09 サノフイ−アベンテイス ベンゾイミダゾール単位を含む三環式ｎ−ヘテロアリール−カルボキサミド誘導体、それらの調製方法およびそれらの治療上の使用
CN103172637A (zh) 2013-03-13 2013-06-26 上海大学 嘧啶并[1,2-a]苯并咪唑类化合物及其制备方法
US20150274660A1 (en) 2014-03-28 2015-10-01 Abbvie Inc. INHIBITORS OF HISTONE METHYLTRANSFERASE G9a

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry Letters，2014年，24(17)，4250-4253
Cell Death & Disease，2013年，4(Feb.)，e519
European Journal of Organic Chemistry，22，2014年，4837-4843
Journalof Medicinal Chemistry，1992年，35(1)，163-172

Also Published As

Publication number Publication date
EP3519393A1 (en) 2019-08-07
AU2024200781A1 (en) 2024-02-29
JP2023022230A (ja) 2023-02-14
AU2017336074A1 (en) 2019-03-28
US20200039961A1 (en) 2020-02-06
CA3037587A1 (en) 2018-04-05
AU2021277619A1 (en) 2021-12-23
AU2021277619B2 (en) 2023-11-09
WO2018064557A1 (en) 2018-04-05
US20220274961A1 (en) 2022-09-01
EP4105203A1 (en) 2022-12-21
JP2019533650A (ja) 2019-11-21
EP3519393B1 (en) 2022-05-18

Similar Documents

Publication Publication Date Title
JP2022110080A (ja) Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物およびその使用方法
JP7187449B2 (ja) Ｅｈｍｔ２阻害剤としての置換された融合二環式または三環式複素環化合物
AU2014254392B2 (en) Substituted benzene compounds
JP7425724B2 (ja) Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物及びその誘導体
US20170355712A1 (en) Amine-substituted aryl or heteroaryl compounds
JP2023036991A (ja) Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物、その塩、及びそれらの合成方法
HK40098892A (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
HK40016100B (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
HK40016100A (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
NZ795530A (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
HK40012431A (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
OA19666A (en) Amine-substituted heterocyclic compounds as Ehmt2 inhibitors and methods of use thereof.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200925

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200925

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210907

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220607

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220906

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221101

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221130

R150 Certificate of patent or registration of utility model

Ref document number: 7187449

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150